{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:57:03Z","timestamp":1791593823482,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jneuroim.2026.578941","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:09:25Z","timestamp":1776575365000},"page":"578941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Real-world evidence on utilization and clinical outcomes of efgartigimod in patients with generalized myasthenia gravis"],"prefix":"10.1016","volume":"417","author":[{"given":"Lauren","family":"Miguet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"De Merlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristl G.","family":"Claeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2026.578941_bb0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/mus.27832","article-title":"Myasthenic crisis","volume":"68","author":"Claytor","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2026.578941_bb0010","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/jnnp-2024-334086","article-title":"Efgartigimod efficacy and safety in refractory myasthenia gravis: UK\u2019s first real-world experience","volume":"96","author":"Dion\u00edsio","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2026.578941_bb0015","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16189","article-title":"Efgartigimod in generalized myasthenia gravis: a real-life experience at a national reference center","volume":"31","author":"Frangiamore","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578941_bb0020","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1007\/s00415-024-12293-5","article-title":"Real-world experience with efgartigimod in patients with myasthenia gravis","volume":"271","author":"Fuchs","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578941_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2026.e00837","article-title":"Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: predictors and treatment strategies","author":"Fuchs","year":"2026","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jneuroim.2026.578941_bb0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","article-title":"New and emerging biological therapies for myasthenia gravis: a focussed review for clinical decision-making","volume":"39","author":"Gerischer","year":"2025","journal-title":"BioDrugs"},{"key":"10.1016\/j.jneuroim.2026.578941_bb0035","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2026.578941_bb0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jneuroim.2026.578941_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.123652","article-title":"Reduction in oral glucocorticoid use after efgartigimod initiation in clinical practice among patients with generalized myasthenia gravis","volume":"477","author":"Goyal","year":"2025","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2026.578941_bb0050","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/acn3.70051","article-title":"Fixed cycles or every-other-week efgartigimod in generalized myasthenia gravis","volume":"12","author":"Habib","year":"2025","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578941_bb0055","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70391","article-title":"Efficacy and safety of efgartigimod for patients with myasthenia gravis in a real-world cohort of 77 patients","volume":"31","author":"Hao","year":"2025","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.jneuroim.2026.578941_bb0060","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2026.578941_bb0065","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578941_bb0070","doi-asserted-by":"crossref","first-page":"18","DOI":"10.17925\/ENR.2018.13.1.18","article-title":"Refractory myasthenia gravis \u2013 patient burden and the need for new therapeutic targets","volume":"13","author":"Jacob","year":"2017","journal-title":"Eur. Neurol. Rev."},{"key":"10.1016\/j.jneuroim.2026.578941_bb0075","first-page":"2422","article-title":"Treating myasthenia gravis beyond the eye clinic","volume":"38","author":"Jacob","year":"2024","journal-title":"Eye (Basingstoke)"},{"key":"10.1016\/j.jneuroim.2026.578941_bb0080","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251319656","article-title":"Patterns and predictors of therapeutic response to efgartigimod in acetylcholine receptor-antibody generalized myasthenia gravis subtypes","volume":"18","author":"Jin","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jneuroim.2026.578941_bb0085","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/mus.27974","article-title":"Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice","volume":"68","author":"Katyal","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2026.578941_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12061214","article-title":"Real-world case series of efgartigimod for Japanese generalized myasthenia gravis: well-tailored treatment cycle intervals contribute to sustained symptom control","volume":"12","author":"Konno","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.jneuroim.2026.578941_bb0095","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1002\/acn3.52142","article-title":"Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China","volume":"11","author":"Luo","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578941_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1472845","article-title":"Efgartigimod treatment for generalized myasthenia gravis: a single-center case series of 16 patients","volume":"15","author":"Nomura","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578941_bb0105","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1007\/s00415-024-12588-7","article-title":"A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients","volume":"271","author":"Pane","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578941_bb0110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.578941_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1555068","article-title":"Real world study in Italian public hospital with efgartigimod in patients affected by generalized myasthenia gravis: influence of clinical and serological factors","volume":"16","author":"Sgarzi","year":"2025","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578941_bb0120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/mus.28003","article-title":"Single institution experience with efgartigimod in patients with myas\u2019thenia gravis: patient selection, dosing schedules, treatment response, and adverse events","volume":"69","author":"Singer","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2026.578941_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2026.1755374","article-title":"Real-world use of efgartigimod in acetylcholine receptor antibody\u2013positive generalized myasthenia gravis: experience from two centers in Greece and Cyprus","volume":"17","author":"Tsokkos","year":"2026","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578941_bb0130","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.578941_bb0135","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40120-025-00748-4","article-title":"Real-world experience with FcRn inhibitors efgartigimod and rozanolixizumab in myasthenia gravis: administration in multiple cycles and transition from intravenous to subcutaneous formulation","volume":"14","author":"Yoshikawa","year":"2025","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.jneuroim.2026.578941_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1223322","article-title":"Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Immunol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826000895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826000895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:55:15Z","timestamp":1784552115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572826000895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":28,"alternative-id":["S0165572826000895"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.578941","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evidence on utilization and clinical outcomes of efgartigimod in patients with generalized myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.578941","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"578941"}}